Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins
Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited and acquired peptide hormone and protein deficiencies. With the exception of therapeutic monoclonal antibodies, these biological medicines a...
Saved in:
Published in | Thrombosis and haemostasis Vol. 99; no. 5; p. 874 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.05.2008
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited and acquired peptide hormone and protein deficiencies. With the exception of therapeutic monoclonal antibodies, these biological medicines are synthesized by cultured cells using DNA sequences that would yield proteins with identical amino acid sequences as endogenous human proteins. Therefore, there was the broad expectation that recombinant human biological medicines would be non-immunogenic in patients capable of synthesizing even sub-optimal levels of these therapeutic proteins to which they are innately tolerant. However, the widespread clinical use of recombinant human proteins has demonstrated that nearly all of them are immunogenic. This observation suggests that factors additional to differences in amino acid sequences of endogenous and biotherapeutic proteins contribute to the immunogenicity of therapeutic proteins. The main aim of this review is to summarize some of the factors that are known to contribute to the immunogenicity of recombinant therapeutic proteins. |
---|---|
AbstractList | Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited and acquired peptide hormone and protein deficiencies. With the exception of therapeutic monoclonal antibodies, these biological medicines are synthesized by cultured cells using DNA sequences that would yield proteins with identical amino acid sequences as endogenous human proteins. Therefore, there was the broad expectation that recombinant human biological medicines would be non-immunogenic in patients capable of synthesizing even sub-optimal levels of these therapeutic proteins to which they are innately tolerant. However, the widespread clinical use of recombinant human proteins has demonstrated that nearly all of them are immunogenic. This observation suggests that factors additional to differences in amino acid sequences of endogenous and biotherapeutic proteins contribute to the immunogenicity of therapeutic proteins. The main aim of this review is to summarize some of the factors that are known to contribute to the immunogenicity of recombinant therapeutic proteins. |
Author | Mukovozov, Ilya Sabljic, Thomas Ofosu, Frederick A Hortelano, Gonzalo |
Author_xml | – sequence: 1 givenname: Ilya surname: Mukovozov fullname: Mukovozov, Ilya organization: Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 3N26, Hamilton, ON, Canada L8N 3Z5 – sequence: 2 givenname: Thomas surname: Sabljic fullname: Sabljic, Thomas – sequence: 3 givenname: Gonzalo surname: Hortelano fullname: Hortelano, Gonzalo – sequence: 4 givenname: Frederick A surname: Ofosu fullname: Ofosu, Frederick A |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18449416$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j81KAzEYRbOo2B_duZa8wGi-JJOZWUqxVii4qeCu5OcbGzHJkMks-vZWtKsD58CFuySzmCIScgfsAUCxx_2WNRVAxVQtZ2TBhGSV4rKek-U4fjEGSnb1NZlDK2UnQS3Ix0bbkvJIy1EXalMs2ZupIC3prJD6EMIU0ydGb3050dT_6qwHnIq3NKNNwfioY6HHKehIh5wK-jjekKtef494-88Ved8879fbavf28rp-2lVWQVMqYU3Xdhp544AbKxoO6NACuNoIFL3QSrrayVowwXuwlhuArjlHLVvFga_I_d_uMJmA7jBkH3Q-HS4X-Q_IcFQZ |
CitedBy_id | crossref_primary_10_1002_jps_22276 crossref_primary_10_1016_j_cbpa_2009_04_627 crossref_primary_10_1002_jps_22123 crossref_primary_10_1586_17474086_2014_963550 crossref_primary_10_1517_17425240903199143 crossref_primary_10_4161_mabs_1_2_7909 crossref_primary_10_1155_2016_1298473 crossref_primary_10_4155_bio_2020_0174 crossref_primary_10_1111_j_1365_2516_2009_02058_x crossref_primary_10_1126_science_abe0075 crossref_primary_10_1016_j_chroma_2009_10_057 crossref_primary_10_1016_j_ejpb_2009_02_014 crossref_primary_10_1517_17425250802525496 crossref_primary_10_1021_ac3026465 crossref_primary_10_1002_pro_680 crossref_primary_10_1016_j_molimm_2021_05_005 crossref_primary_10_1057_jgm_2010_10 crossref_primary_10_1016_j_bbamcr_2009_01_007 crossref_primary_10_1016_j_exphem_2009_02_011 crossref_primary_10_1017_cts_2020_493 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1160/TH07-11-0654 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 18449416 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review |
GroupedDBID | --- .55 .GJ 0R~ 0VX 123 1KJ 4.4 53G 5RE AAQQT ABJNI ABOCM ACGFO ACGFS ACNUY AENEX AFFNX AGCGI AHRSK ALMA_UNASSIGNED_HOLDINGS BR6 C45 CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P H13 J5H NPM OVD P2P RTC RTE SJN TEORI X7M ZGI ZXP |
ID | FETCH-LOGICAL-c617t-3cb989ae27d12bc3721edec11d5b3e3f3a64d5d453032f1cc2b11975b3a486212 |
ISSN | 0340-6245 |
IngestDate | Mon Jul 21 05:47:04 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c617t-3cb989ae27d12bc3721edec11d5b3e3f3a64d5d453032f1cc2b11975b3a486212 |
PMID | 18449416 |
ParticipantIDs | pubmed_primary_18449416 |
PublicationCentury | 2000 |
PublicationDate | 2008-05-01 |
PublicationDateYYYYMMDD | 2008-05-01 |
PublicationDate_xml | – month: 05 year: 2008 text: 2008-05-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | Thrombosis and haemostasis |
PublicationTitleAlternate | Thromb Haemost |
PublicationYear | 2008 |
SSID | ssj0016495 |
Score | 2.0818083 |
SecondaryResourceType | review_article |
Snippet | Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 874 |
SubjectTerms | Animals Antibodies - metabolism Antibody Formation Chemistry, Pharmaceutical Cloning, Molecular Dosage Forms Drug Administration Routes Drug Contamination Drug Stability Drug Storage Humans Polyethylene Glycols - chemistry Protein Processing, Post-Translational Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - biosynthesis Recombinant Fusion Proteins - chemistry Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - therapeutic use T-Lymphocytes - immunology |
Title | Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins |
URI | https://www.ncbi.nlm.nih.gov/pubmed/18449416 |
Volume | 99 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLY6kBAXBIwxxg_5wK3KmBM7P45o2qgmjQud1FtlO46arq2nNZu0nveH7z3HbkMZCLhEkZ1Ebb7P1nsv33uPkM8F1jTLyjQC2zWLeClMVMhMRYlOeGaYUNwlhZ1_TwcX_GwkRr3efUe1dNOoQ716NK_kf1CFMcAVs2T_Adn1Q2EAzgFfOALCcPwrjE99s5xmAm6-E51j9yoT7Ml6jskfFm6vtVdedNKt-ugLz5VTwvhWfa5oQ-3jd9PAo2u4ymLdEoyxT6SZW7Aol_Vyg9WlvbUre-v2m9ndeqP_IdVsWustHZLT6l43ZiZd1-_-N7tYyZldR3sru7xpTWqsc1HrSx9uDaGJfCMEDClZmFsQt_Uiw3bb9kPytBKdvTNv2_X8uqenKIIcDrCaJaq0xE-XASJXc4cv-Kq84G3m5p9ntypsh6kdsgO-BjZPxYiP_xKVcte5Z_1XQvJEevSl-5Ow-Kx_zJaD4gyV4UvywnsY9GtLl1ekZxavybNzr6HYJSPPGoqsoRvW0MbCkKFbrKG2oh3W0A5rqGMNDax5Qy5OT4bHg8j314g02K0NrEdV5IU0cVayWOkkixkAqxkrhUpMUiUyhcVbcgFmTlwxrWOFH51hUnJwhFm8R54s7MLsEypyVWWiQHFAxVmhcyMKJsH1yIzhKU_fkbftOxlftUVUxuFtHfx25j15viHVB_K0glVrPoIJ2KhPDqMHsvxdYQ |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+that+contribute+to+the+immmunogenicity+of+therapeutic+recombinant+human+proteins&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Mukovozov%2C+Ilya&rft.au=Sabljic%2C+Thomas&rft.au=Hortelano%2C+Gonzalo&rft.au=Ofosu%2C+Frederick+A&rft.date=2008-05-01&rft.issn=0340-6245&rft.volume=99&rft.issue=5&rft.spage=874&rft_id=info:doi/10.1160%2FTH07-11-0654&rft_id=info%3Apmid%2F18449416&rft_id=info%3Apmid%2F18449416&rft.externalDocID=18449416 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon |